Codexis (4QK) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4QK Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Codexis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4QK Stock 12 Month Forecast

Average Price Target

€6.00

▲(358.37% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Codexis in the last 3 months. The average price target is €6.00 with a high forecast of €9.44 and a low forecast of €1.72. The average price target represents a 358.37% change from the last price of €1.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","-1":"-€1","1.75":"€1.75","4.5":"€4.5","7.25":"€7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9.4359045,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€9.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.0046665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.715619,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.194,1.8279926538461537,2.4619853076923075,3.0959779615384617,3.7299706153846155,4.363963269230769,4.9979559230769235,5.631948576923077,6.265941230769231,6.899933884615385,7.533926538461539,8.167919192307693,8.801911846153846,{"y":9.4359045,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.194,1.5640512692307693,1.9341025384615385,2.3041538076923076,2.674205076923077,3.0442563461538463,3.4143076153846152,3.7843588846153846,4.154410153846154,4.524461423076923,4.894512692307693,5.264563961538462,5.6346152307692305,{"y":6.0046665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.194,1.2341245384615385,1.274249076923077,1.3143736153846153,1.3544981538461538,1.3946226923076923,1.4347472307692308,1.4748717692307691,1.5149963076923076,1.5551208461538462,1.5952453846153847,1.6353699230769232,1.6754944615384617,{"y":1.715619,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.094,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.042,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.408,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.372,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.872,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.479,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.382,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.286,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.072,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.194,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€9.44

Average Price Target€6.00

Lowest Price Target€1.72

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Allison Bratzel

Piper Sandler

€7.72→€6.86

Buy

423.85%

Upside

Reiterated

08/17/26

Codexis price target lowered to $8 from $9 at Piper SandlerCodexis price target lowered to $8 from $9 at Piper Sandler

Brendan Smith

TD Cowen

€1.72

Hold

30.96%

Upside

Reiterated

08/11/26

Analysts Conflicted on These Healthcare Names: C4 Therapeutics (NASDAQ: CCCC), Codexis (NASDAQ: CDXS) and LENZ Therapeutics (NASDAQ: LENZ)

Kristen Kluska

Cantor Fitzgerald

€9.44

Buy

620.30%

Upside

Reiterated

08/11/26

Cantor Fitzgerald Keeps Their Buy Rating on Codexis (CDXS)

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

07/24/26

Analysts Are Bullish on These Healthcare Stocks: Codexis (CDXS), RegenXBio (RGNX)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€3

Buy

129.19%

Upside

Assigned

04/01/26

Codexis (CDXS) Gets a Buy from Jefferies

Robert Wasserman

Benchmark Co.

―

Hold

―

Reiterated

11/14/25

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Codexis (NASDAQ: CDXS) and Oric Pharmaceuticals (NASDAQ: ORIC)

Daniel Arias

Stifel Nicolaus

€4.29

Buy

227.41%

Upside

Reiterated

11/10/25

Stifel Nicolaus Reaffirms Their Buy Rating on Codexis (CDXS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Allison Bratzel

Piper Sandler

€7.72→€6.86

Buy

423.85%

Upside

Reiterated

08/17/26

Codexis price target lowered to $8 from $9 at Piper SandlerCodexis price target lowered to $8 from $9 at Piper Sandler

Brendan Smith

TD Cowen

€1.72

Hold

30.96%

Upside

Reiterated

08/11/26

Analysts Conflicted on These Healthcare Names: C4 Therapeutics (NASDAQ: CCCC), Codexis (NASDAQ: CDXS) and LENZ Therapeutics (NASDAQ: LENZ)

Kristen Kluska

Cantor Fitzgerald

€9.44

Buy

620.30%

Upside

Reiterated

08/11/26

Cantor Fitzgerald Keeps Their Buy Rating on Codexis (CDXS)

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

07/24/26

Analysts Are Bullish on These Healthcare Stocks: Codexis (CDXS), RegenXBio (RGNX)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€3

Buy

129.19%

Upside

Assigned

04/01/26

Codexis (CDXS) Gets a Buy from Jefferies

Robert Wasserman

Benchmark Co.

―

Hold

―

Reiterated

11/14/25

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX), Codexis (NASDAQ: CDXS) and Oric Pharmaceuticals (NASDAQ: ORIC)

Daniel Arias

Stifel Nicolaus

€4.29

Buy

227.41%

Upside

Reiterated

11/10/25

Stifel Nicolaus Reaffirms Their Buy Rating on Codexis (CDXS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Codexis

3 Months

Matt HewittCraig-Hallum

Success Rate

12/27 ratings generated profit

Average Return

+1.69%

Copying Matt Hewitt's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +1.69% per trade.

1 Year

Matt HewittCraig-Hallum

Success Rate

10/27 ratings generated profit

Average Return

-2.34%

Copying Matt Hewitt's trades and holding each position for 1 Year would result in 37.04% of your transactions generating a profit, with an average return of -2.34% per trade.

2 Years

Matt HewittCraig-Hallum

Success Rate

4/27 ratings generated profit

Average Return

-25.80%

Copying Matt Hewitt's trades and holding each position for 2 Years would result in 14.81% of your transactions generating a profit, with an average return of -25.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4QK Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4QK has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 4QK average Analyst price target in the past 3 months is 6.00.

Each month's total comprises the sum of three months' worth of ratings.

4QK Financial Forecast

4QK Earnings Forecast

Next quarter’s earnings estimate for 4QK is -€0.08 with a range of -€0.13 to -€0.06. The previous quarter’s EPS was -€0.11. 4QK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4QK has Performed in-line its overall industry.

4QK Sales Forecast

Next quarter’s sales forecast for 4QK is €16.08M with a range of €13.27M to €18.31M. The previous quarter’s sales results were €12.88M. 4QK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4QK has Performed in-line its overall industry.

4QK Stock Forecast FAQ

What is DE:4QK’s average 12-month price target, according to analysts?

Based on analyst ratings, Codexis’s 12-month average price target is 6.00.

What is DE:4QK’s upside potential, based on the analysts’ average price target?

Codexis has 358.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Codexis a Buy, Sell or Hold?

Codexis has a consensus rating of Strong Buy, which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is Codexis’s share price target?

The average share price target for Codexis is 6.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €9.44 ,and the lowest forecast is €1.72. The average share price target represents 358.37% Increase from the current price of €1.31.

What do analysts say about Codexis?

Codexis’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Codexis?

To buy shares of DE:4QK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Codexis (4QK) Stock Forecast & Price Target

4QK Analyst Ratings

4QK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Codexis

4QK Analyst Recommendation Trends

4QK Financial Forecast

4QK Earnings Forecast

4QK Sales Forecast

4QK Stock Forecast FAQ

Detailed List of Analyst Forecasts